Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis. A BLA was submitted in June 2013 seeking approval for vedolizumab for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). The application submitted for vedolizumab for the treatment of adults with moderately to severely active CD will be reviewed by the FDA under the standard review timeline.  

An application can receive Priority Review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority Review status allows for an eight month review period from the date of submission, compared to the standard review period of 12 months.

"Additional treatment options are needed for ulcerative colitis, and the acceptance for Priority Review of vedolizumab underscores this need," said Karen Lasch, M.D., medical director - GI, Medical Affairs, U.S. Region, Takeda. "Takeda is excited about the potential for vedolizumab and, if approved, the possibility of providing a new treatment option for people with CD and UC."

CD and UC are the two most common types of inflammatory bowel disease (IBD), and can be both painful and debilitating, sometimes leading to serious complications. While CD and UC treatment options are available, many patients may not achieve or maintain remission of their disease. 
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision ... (EP) mapping and ablation device market will ... ablation to treat atrial fibrillation (AF). The ... treatment option for AF will spur adoption ... application, such as advanced loop diagnostic catheters, ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
(Date:8/21/2014)... August 21, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Dianeal ... US FDA announced on August 15, that two lots ... 2.5% Dextrose 5000mL (Ambu-Flex II), by Baxter International Inc., ... particulate matter. , The reason for the recall ...
(Date:8/21/2014)... TX (PRWEB) August 21, 2014 Sometimes you have ... , In his new book “From Zero to a Hundred: Finding ... officer, shares his story of surviving a broken family, a childhood ... brings affirmation of who you were created to be,” Roy said. ... which is why I know my purpose today of helping others ...
(Date:8/21/2014)... 2014 OpsAssure, the local start-up ... to participate in the Harbor Accelerator's 14 week ... sessions and valuable resources.he Harbor’s goal is to ... Each start-up selected for the program receives a ... help businesses grow quickly, test markets and become ...
(Date:8/21/2014)... Today, Fecbek.com, a leading wedding dresses ... of wedding dresses. And all these elegant, gorgeous and ... excellent designers. , A wedding dress or wedding gown ... wedding ceremony. Color, style and ceremonial importance of the ... the wedding participants. In order to satisfy every customer, ...
(Date:8/20/2014)... Fancyflyingfox.com, the popular online supplier of wedding ... a new collection of 2014 military ball gowns ... promotion for these trendy and elegant products. , ... special offer to show its appreciation to the global ... ball outfits are provided with deeply discounted prices, up ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Elegant Wedding Dresses Are for Sale at Fecbek.com 2Health News:2014 Military Ball Gowns Offered At Popular Online Store Fancyflyingfox.com 2
... VIRGINIA BEACH, Va., June 10 AMERIGROUP,Corporation (NYSE: ... full-year,2008 guidance of $2.35 to $2.45 per diluted share ... of Tennessee. As previously,announced, the Company will present at ... In the first quarter of 2008, AMERIGROUP disclosed higher ...
... of Christopher,Grell have filed a lawsuit against Herbalife Ltd. ... State of California (case BC392373, dept. 48) today,on behalf ... after,taking Herbalife products., The lawsuit, which also names ... Phillis Chen, a resident,of the State of California, suffered ...
... June 10 Mylan Inc. (NYSE: MYL ),announced ... Federal Circuit has,affirmed a May 2007 District Court ruling ... capsules do not infringe patents asserted,against Mylan by AstraZeneca. ... Mylan launched its Omeprazole products on August 4, 2003, ...
... June 10 More and more people today ... difficult to get and,stay healthy. This National Men,s ... that are helping people who are uninsured but,need ... this report from Pfizer (NYSE: PFE ) ...
... items keep addiction affordable, study says , , ... the United States have declined in recent years, but ... the decline in cigarette sales by 30 percent, a ... analyzed federal government data and found that between 2000 ...
... helped with depression, agitation in elderly , , TUESDAY, June ... may ease some of the behavioral problems associated with ... a hormone which seems to play a role in ... night. , Both strategies could greatly improve quality of ...
Cached Medicine News:Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 2Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 3Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 4Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 5Health News:Herbalife Sued for Negligence and Fraud by Victim 2Health News:Decline in Cigarette Sales Offset by Use of Alternative Products 2Health News:Adding Light Eases Behavioral Problems of Dementia 2Health News:Adding Light Eases Behavioral Problems of Dementia 3
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. The ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
... InstaCheck® multi-drug test device provides ... easily. Negative results can be ... 3 minutes; positive results require ... one-time urine sample application will ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
Medicine Products: